PARP1 and cancer: While healthy cells with intact HR mechanisms can withstand PARP inhibition due to their ability to repair DNA through HR, cancer cells with BRCA mutations and impaired HR pathways rely heavily on alternative repair mechanisms such as the low-fidelity repair system non-homologous end-joining, which often results in accumulation of incorrectly repaired DSBs and eventually cell death (5).